Furthermore, axitinib, a therapeutic agent that targets VEGFRs (including VEGFR3), shows antitumor activity against myxoid liposarcoma cell lines and significantly reduces the growth of MLS 1765 xenografts in mice. Here, FLT4 is linked to myxoid liposarcoma.